Published in Bone Marrow Transplant on February 01, 2000
Progressive neurological disease induced by tacrolimus in a renal transplant recipient: case presentation. BMC Nephrol (2006) 1.15
Reversible encephalopathy after cardiac transplantation: histologic evidence of endothelial activation, T-cell specific trafficking, and vascular endothelial growth factor expression. AJNR Am J Neuroradiol (2008) 1.11
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Laparoscopic cholecystectomy using fine-caliber instruments. Surg Endosc (1998) 6.62
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Infection of human cells by an endogenous retrovirus of pigs. Nat Med (1997) 5.71
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A (2000) 4.88
High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol (1995) 4.59
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem (1995) 3.27
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (1996) 2.96
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Simple method for quantitation of enhanced vascular permeability. Proc Soc Exp Biol Med (1970) 2.93
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis (1985) 2.86
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Two sets of human-tropic pig retrovirus. Nature (1997) 2.74
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy (2006) 2.52
Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.52
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (2001) 2.46
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol (2001) 2.37
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet (1998) 2.32
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Endoscopic submucosal dissection for early gastric cancer performed by supervised residents: assessment of feasibility and learning curve. Endoscopy (2009) 2.20
Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.18
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol (1999) 2.15
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01
Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke (1996) 2.00
Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Mapping of quantitative trait loci controlling low-temperature germinability in rice (Oryza sativa L.). Theor Appl Genet (2003) 1.92
Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A (2001) 1.87
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Identification and characterization of genes encoding polycyclic aromatic hydrocarbon dioxygenase and polycyclic aromatic hydrocarbon dihydrodiol dehydrogenase in Pseudomonas putida OUS82. J Bacteriol (1994) 1.83
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82
Small "flat adenoma" of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum (1985) 1.82
Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81
Pseudocompact-type growth and conversion of growth types of strains of Staphylococcus aureus in vitro and in vivo. J Bacteriol (1969) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81
Comparison of Compact and Diffuse Variants of Strains of Staphylococcus aureus. Infect Immun (1970) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80